Tilray stock fell pre-market as analysts weighed upbeat Q3 results against regulatory pressures. Alliance Global lowered its price target to $7, citing uncertainty over US hemp restrictions. However, Roth Capital upgraded the stock to 'Buy', praising Tilray's strong international performance. Tightening hemp regulations in several US states pose a potential headwind.